Refractory myasthenia gravis exacerbation triggered By pembrolizumab

Muscle Nerve. 2018 Apr;57(4):E120-E121. doi: 10.1002/mus.26021. Epub 2017 Dec 7.

Authors

Damien E Earl^{1

2}, Aaron I Loochtan^{1

2}, Richard S Bedlack^{1

2}

Affiliations

¹ Department of Neurology, Duke University Hospital, Durham, North Carolina, USA.
² Department of Neurology, Durham Veterans Affairs Medical Center, Durham, North Carolina, USA.

PMID: 29193151
DOI: 10.1002/mus.26021

No abstract available

Keywords: exacerbation; immune checkpoint inhibitor; immune-related adverse event; melanoma; myasthenia gravis; pembrolizumab.

Publication types

Case Reports

MeSH terms

Aged
Antibodies, Monoclonal, Humanized / adverse effects*
Antineoplastic Agents, Immunological / adverse effects*
Disease Progression
Head and Neck Neoplasms / drug therapy
Head and Neck Neoplasms / pathology
Humans
Liver Neoplasms / drug therapy*
Liver Neoplasms / secondary
Lung Neoplasms / drug therapy*
Lung Neoplasms / secondary
Male
Melanoma / drug therapy*
Melanoma / secondary
Myasthenia Gravis / chemically induced*
Scalp
Skin Neoplasms / drug therapy*
Skin Neoplasms / pathology

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
pembrolizumab